Please assess the completion status of the following clinical trial:

Trial Title: Dose Finding Study of HP802-247 in Venous Leg Ulcers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Provide informed consent.~* Willing to comply with protocol instructions, including allowing all study assessments.~* Have a venous leg ulcer (venous etiology)between the knee and ankle, at or above the malleolus.~* Venous insufficiency confirmed by duplex Doppler ultrasound examination for valvular or venous incompetence.~* Target ulcer duration greater than or equal to 6 weeks but less than or equal to 24 months.~Exclusion Criteria:~* Women who are pregnant or lactating~* Therapy with another investigational agent within thirty (30) days of Screening, or during the study.~* A target ulcer of non-venous etiologies.~* Refusal of or inability to tolerate compression therapy.~* Therapy of the target ulcer with tissue-engineered cell-based skin equivalents within 30 days preceding the Screening Visit.~* Therapy of the target ulcer with topical growth factors within 1 week preceding the Screening Visit.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A - Low Q7D (Type: EXPERIMENTAL): Low dose HP802-247, applied at each visit
- B - Low Q14D (Type: EXPERIMENTAL): Low dose HP802-247 applied at Visits 1, 3, 5, 7, 9, 11 and Placebo at Visits 2, 4, 6, 8, 10, and 12
- C - High Q7D (Type: EXPERIMENTAL): High dose HP802-247, applied at each visit
- D - High Q14D (Type: EXPERIMENTAL): High dose HP802-247, applied at Visits 1, 3, 5, 7, 9, 11 and Placebo at Visits 2, 4, 6, 8, 10, and 12
- E - Vehicle (Type: PLACEBO_COMPARATOR): Placebo (Vehicle), applied at each visit

Based on this trial design, predict the completion outcome and termination type (if applicable).